Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Glioma × sargramostim × Clear all

Phase

Status

Sponsor Class

OTHER 5 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 5 Glioblastoma 4 Breast Neoplasms 3 Pathologic Complete Response 2 Ovarian Neoplasms 2 Neoplasms 2 Multiple Myeloma 2 Melanoma 2 Lung Neoplasms 2 Gliosarcoma 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Wilms Tumor 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Smoldering Multiple Myeloma 1 Small Cell Lung Carcinoma 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Lymphoma, Follicular 1 Glioma 1 Brain Neoplasms 1 Advanced Ovarian Cancer 1 Advanced Cancer 1

Interventions

Temozolomide 28 Bevacizumab 10 Radiotherapy 9 Surgical Procedures, Operative 6 Lomustine 6 IL13-PE38 6 Carboplatin 6 TIC10 compound 5 vorasidenib 4 trametinib 4 dabrafenib 4 Flucytosine 4 Dianhydrogalactitol 4 Chlorotoxin 4 vocimagene amiretrorepvec 3 Radiation 3 Paclitaxel 3 OKN 007 3 Irinotecan 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Cyclophosphamide 3 CLR1404 3 trans-sodium crocetinate 2 pembrolizumab 2 marizomib 2 lenvatinib 2 enzastaurin 2 contrast agent BR1 2 avapritinib 2 abemaciclib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00458601 2018-01-16

ACT III

Celldex Therapeutics

Phase 2 Completed

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡